

## Assoc. Prof. Zeliha PALA KARA

### Personal Information

**Office Phone:** [+90 212 440 0000](tel:+902124400000) Extension: 13422

**Fax Phone:** [+90 212 527 1825](tel:+902125271825)

**Email:** [zpala@istanbul.edu.tr](mailto:zpala@istanbul.edu.tr)

**Web:** <http://aves.istanbul.edu.tr/zpala/>

**Address:** İstanbul Üniversitesi Eczacılık Fakültesi Farmakoloji Abd Beyazıt/İstanbul

### International Researcher IDs

ORCID: 0000-0001-7898-5602

Publons / Web Of Science ResearcherID: AAD-7791-2020

Yoksis Researcher ID: 165739

### Education Information

Doctorate, Istanbul University, Faculty Of Pharmacy , Farmakoloji Abd, Turkey 2004 - 2009

Postgraduate, Istanbul University, Faculty Of Pharmacy , Farmakoloji Abd, Turkey 2001 - 2004

Undergraduate, Istanbul University, Faculty Of Pharmacy , Turkey 1997 - 2001

### Foreign Languages

English, C1 Advanced

### Dissertations

Doctorate, ABC gen familyasına dahil olan Bcrp1 ve Mrp-2 taşıyıcı proteinlerinin antineoplastik bir ilaç olan metotreksatın farmakokinetiğine etkisi, Istanbul University, Health Sciences Institute, Farmakoloji Abd, 2009

Postgraduate, Simvastatin ve talinolol arasında P-glikoproteine bağlı olası bir farmakokinetik etkileşmenin incelenmesi, Istanbul University, Health Sciences Institute, Farmakoloji Abd, 2004

### Research Areas

Health Sciences, Pharmacology and Therapeutics, Professional Sciences, Pharmacology

### Academic Titles / Tasks

Associate Professor, Istanbul University, Faculty Of Pharmacy , Department Of Professional Pharmaceutical Sciences, 2023 - Continues

Assistant Professor, Istanbul University, Faculty Of Pharmacy , Department Of Professional Pharmaceutical Sciences, 2018 - 2023

Assistant Professor, Istanbul University, Faculty of Pharmacy , Department of Professional Pharmaceutical Sciences, 2015 - 2018

Research Assistant PhD, Istanbul University, Faculty of Pharmacy , Department of Professional Pharmaceutical Sciences,

2009 - 2015

Research Assistant, Istanbul University, Faculty of Pharmacy , Department of Professional Pharmaceutical Sciences, 2002 - 2009

Expert, Universiteit van Amsterdam, The Netherland Cancer Institute, Deneyisel Tedavi Bölümü, 2006 - 2007

## Advising Theses

Pala Kara Z., HİDROKSİKLOKİDİN'İN P-GLİKOPROTEİN SUBSTRATI TALİNOLOLÜN FARMAKOKİNETİĞİNE ETKİSİ, Postgraduate, M.SAEED(Student), 2022

PALA KARA Z., MEME VEYA KOLOREKTAL KANSERLİ HASTALARDA KARBOKSİESTERAZ ENZİMİ POLİMORFİZMİ İLE KAPESİTABİNİN FARMAKOKİNETİĞİ VE YAN ETKİ GÖRÜLME SIKLIĞI ARASINDAKİ İLİŞKİNİN DEĞERLENDİRİLMESİ, Postgraduate, M.Kurtan(Student), 2018

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Diurnal Changes in Capecitabine Clock-Controlled Metabolism Enzymes Are Responsible for Its Pharmacokinetics in Male Mice**  
Akyel Y. K., Ozturk Civelek D., Ozturk Seyhan N., Gul Ş., Gazioglu I., Pala Kara Z., Lévi F., Kavakli I. H., Okyar A.  
JOURNAL OF BIOLOGICAL RHYTHMS, vol.38, no.2, pp.171-184, 2023 (SCI-Expanded)
- II. **Dosing-time dependent testicular toxicity of everolimus in mice**  
Ozturk N., Civelek D. O., Sancar S., Kaptan E., Kara Z., Okyar A.  
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.165, 2021 (SCI-Expanded)
- III. **The effects of P-glycoprotein inhibitor zosuquidar on the sex and time-dependent pharmacokinetics of parenterally administered talinolol in mice**  
Pala K., Ozturk C., Ozturk N., Okyar A.  
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.156, 2021 (SCI-Expanded)
- IV. **Effects of atorvastatin on talinolol absorption: A potential drug-drug interaction.**  
Kara Z., Ozturk D., Ozturk N., Orman M., Baktir G., Okyar A.  
Die Pharmazie, vol.75, pp.70-74, 2020 (SCI-Expanded)
- V. **Association between ABCB1, ABCG2 carrier protein and COX-2 enzyme gene polymorphisms and breast cancer risk in a Turkish population.**  
Zeliha K. P., Dilek O., Ezgi O., Halil K., Cihan U., Gul O.  
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, vol.28, no.2, pp.215-219, 2020 (SCI-Expanded)
- VI. **Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.**  
Okyar A., Kumar S. A., Filipski E., Piccolo E., Ozturk N., Xandri-Monje H., Pala Z., Abraham K., Gomes A. R. G. D. J., Orman M. N., et al.  
Scientific reports, vol.9, pp.10505, 2019 (SCI-Expanded)
- VII. **The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus**  
Ozturk N., Öztürk D., Pala-Kara Z., Kaptan E., Sancar-Bas S., Ozsoy N., Cinar S., Deniz G., Li X., Giacchetti S., et al.  
Chronobiology International, vol.35, pp.705-718, 2018 (SCI-Expanded)
- VIII. **Pharmacokinetics of talinolol is modified by barnidipine: implication of P-glycoprotein modulation**  
Ozturk N., Öztürk D., Pala-Kara Z., Okyar A.  
PHARMAZIE, vol.72, no.1, pp.29-34, 2017 (SCI-Expanded)
- IX. **Association Between Human Telomerase Reverse Transcriptase Gene Variations and Risk of Developing Breast Cancer.**  
Oztas E., Kara H., Kara Z., Aydogan M. U., Uras C., Ozhan G.  
Genetic testing and molecular biomarkers, vol.20, no.8, pp.459-64, 2016 (SCI-Expanded)

- X. **Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study**  
PILANCI K. N., Saglam S., Okyar A., YÜCEL S., Pala-Kara Z., Ordu C., Namal E., CIFTCI R., Iner-Koksal U., Kaytan-Saglam E.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.78, no.1, pp.143-150, 2016 (SCI-Expanded)
- XI. **Carbon tetrachloride induced kidney damage and protective effect of *Amaranthus lividus* L. in rats**  
YILMAZ ÖZDEN T., CAN A., KARATUĞ A., PALA KARA Z., OKYAR A., BOLKENT Ş.  
TOXICOLOGY AND INDUSTRIAL HEALTH, pp.1-10, 2014 (SCI-Expanded)
- XII. **Impact of Abcc2 [Multidrug Resistance-Associated Protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (Breast Cancer Resistance Protein) on the Oral Pharmacokinetics of Methotrexate and Its Main Metabolite 7-Hydroxymethotrexate**  
Vlaming M. L. H., van Esch A., van de Steeg E., Pala Z., Wagenaar E., van Tellingen O., Schinkel A. H.  
DRUG METABOLISM AND DISPOSITION, vol.39, no.8, pp.1338-1344, 2011 (SCI-Expanded)
- XIII. **The Effect of Terpenes on Percutaneous Absorption of Tiaprofenic Acid Gel**  
Okyar A., Nuriyev M., Yildiz A., Pala-Kara Z., Ozturk N., Kaptan E.  
ARCHIVES OF PHARMACAL RESEARCH, vol.33, no.11, pp.1781-1788, 2010 (SCI-Expanded)
- XIV. **Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo**  
Vlaming M. L. H., van Esch A., Pala Z., Wagenaar E., van de Wetering K., van Tellingen O., Schinkel A. H.  
MOLECULAR CANCER THERAPEUTICS, vol.8, no.12, pp.3350-3359, 2009 (SCI-Expanded)
- XV. **Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo**  
Vlaming M. L. H., Pala Z., van Esch A., Wagenaar E., de Waart D. R., van de Wetering K., van der Kruijsen C. M. M., Elferink R. P. J. O., van Tellingen O., Schinkel A. H.  
CLINICAL CANCER RESEARCH, vol.15, no.9, pp.3084-3093, 2009 (SCI-Expanded)
- XVI. **Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate**  
Vlaming M. L. H., Pala Z., van Esch A., Wagenaar E., van Tellingen O., de Waart D. R., Elferink R. P. J. O., van de Wetering K., Schinkel A. H.  
CLINICAL CANCER RESEARCH, vol.14, no.24, pp.8152-8160, 2008 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Teranostik Radyofarmasötiklerin Biyodağılımlarında İlaça Bağlı Değişiklikler**  
Pala Kara Z., Şen M.  
NUCLEAR MEDICINE SEMINARS, no.9, pp.49-57, 2023 (Peer-Reviewed Journal)
- II. **Evaluation of the role of the pharmacists in the rational use of inhaler devices in the treatment of asthma and COPD**  
ÖZTÜRK SEYHAN N., Eksi E. S., PALA KARA Z., Dogan B. S. U.  
ISTANBUL JOURNAL OF PHARMACY, no.3, pp.349-356, 2022 (ESCI)
- III. **The Association of ABCC5 and ABCC11 Polymorphisms with The Pharmacokinetics of 5-FU in Advanced Gastric Cancer Patients**  
Kara Z., Oztas E., ÖZTÜRK D., Akyel Y. K., Turna H., Okyar A., Ozhan G.  
CLINICAL AND EXPERIMENTAL HEALTH SCIENCES, vol.10, no.3, pp.285-291, 2020 (ESCI)
- IV. **The role of pharmacists in the management of autism spectrum disorder: A survey to determine the knowledge and perception of the parents**  
Kara Z., Cakir B., Durman D., Dogan B. S.  
ISTANBUL JOURNAL OF PHARMACY, vol.49, no.3, pp.180-185, 2019 (ESCI)
- V. **Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients.**

## Supported Projects

- OKYAR A., ÖZTÜRK N., SANCAR BAŞ S., ÖZTÜRK D., KAPTAN E., PALA KARA Z., Project Supported by Higher Education Institutions, Everolimusun sıçan karaciğerindeki kronotoksitesitesi, 2017 - 2019
- OKYAR A., ÖZTÜRK N., PALA KARA Z., ÖZTÜRK F., LEVİ F., ÖZTÜRK D., AKYEL Y. K., Project Supported by Higher Education Institutions, mTOR inhibitörü everolimusun yaşa bağlı farmakokinetiğinin incelenmesi, 2017 - 2019
- YILDIZ PEKÖZ A., OKYAR A., PALA KARA Z., ÖZTÜRK N., ŞAHİN G., Project Supported by Higher Education Institutions, SEVİME LİN İÇEREN BİYOADHEZİF MUKOZAL DOZAJ FORMLARI: İN VİTRO DEĞERLENDİRİLMESİ VE İN VİVO OLARAK KSEROSTAMİ ÜZERİNE ETKİSİNİN ARAŞTIRILMASI, 2015 - 2018
- YILDIZ PEKÖZ A., PALA KARA Z., ÖZHAN G., AKBAL DAĞISTAN Ö., ŞAHİN G., Project Supported by Higher Education Institutions, Kronik Obstruktif Akciğer Hastalığında C vitamini Transport Sisteminin Etkisi, 2015 - 2018
- OKYAR A., LEVİ F., ÖZTÜRK N., Project Supported by Higher Education Institutions, Everolimusun P-gp ekspresyonuna etkisinin mdr1a:FLuc farelerde incelenmesi, 2016 - 2017
- ÖZTÜRK SEYHAN N., KAPTAN E., Lİ X., LÉVİ F., PALA KARA Z., ÖZTÜRK D., SANCAR BAŞ S., OKYAR A., Project Supported by Higher Education Institutions, Dosing-Time Dependent Reproductive Toxicity of Everolimus in Male Mice, 2016 - 2017
- ÖZHAN G., ÖZTAŞ E., PALA KARA Z., OKYAR A., KARA H., ÖZTÜRK D., ARICI M., Project Supported by Higher Education Institutions, Telomeraz Ters Transkriptaz (TERT) Enzimi ve P-Glikoprotein (MDR1) Taşıyıcı Proteininin Meme Kanseri Oluşumu ve İlaç (Everolimus) Direnci Üzerine Etkisinin Araştırılması, 2015 - 2017
- ÖZHAN G., PALA KARA Z., KARA H., Project Supported by Higher Education Institutions, COX2 GENE VARIATIONS AND RISK OF DEVELOPING BREAST CANCER, 2016 - 2016
- CAN A., ALTINCIK A., KURT ŞİRİN Ö., TUNALI S., AKEV N., YANARDAĞ R., SANCAR BAŞ S., BOLKENT Ş., HASBAL G., SÖNMEZ F., et al., Project Supported by Higher Education Institutions, Vanadyum sülfatın diabetik sıçanların mide ve akciğer dokuları üzerine biokimyasal etkileri, 2015 - 2016
- OKYAR A., ÖZHAN G., PALA KARA Z., Project Supported by Higher Education Institutions, Sisplatin/5-FU kemoterapi rejiminin mide kanserli hastalardaki farmakokinetiğinin değerlendirilmesi, 2012 - 2016

## Memberships / Tasks in Scientific Organizations

Türk Farmakoloji Derneği, Member, 2002 - Continues

## Scientific Consultations

İstanbul Üniversitesi Dış Hekimliği Fakültesi , Other, Istanbul University, Faculty Of Pharmacy , Department of Professional Pharmaceutical Sciences, Turkey, 2014 - Continues

Türkiye İlaç ve Tıbbi Cihaz Kurumu, Scientific Consultancy, Istanbul University, Faculty Of Pharmacy , Department of Professional Pharmaceutical Sciences, Turkey, 2011 - 2015

## Scholarships

Yurtdışı araştırma bursu, Foundation, 2010 - 2010

Yurtdışı doktora araştırma bursu, TÜBİTAK, 2006 - 2007

## Non Academic Experience

SAĞLIK BAKANLIĞI

Antoni van Leeuwenhoek Kanser Hastanesi, Amsterdam, Hollanda

Hollanda Kanser Enstitüsü, Deneysel Tedavi Bölümü, Amsterdam, Hollanda